Germany Liver Cancer Therapeutics Market Analysis

Germany Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Germany Liver Cancer Therapeutics market will reach a value of $346.8 Mn from $107.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30. Liver Cancer Therapeutics in Germany is dominated by a few domestic pharmaceutical companies such as Bayer AG, Merck KGaA and Affimed. The Liver Cancer Therapeutics market in Germany is segmented into different types of cancer and different therapy type. Some of the major factors affecting the German Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10DEPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Vishwa Modhia

Buy Now

Germany Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Germany Liver Cancer Therapeutics market will reach a value of $346.8 Mn from $107.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30.

Germany is a high-income, developed country located in the heart of Western Europe. According to the most recent WHO data, 8,057 people died from liver cancer in Germany in 2020, accounting for 1.15 % of all deaths. With an age-adjusted death rate of 4.03 per 100,000 inhabitants, Germany ranks 129th in the world.

Liver cancer, also known as hepatocellular carcinoma (HCC), is a major health concern in Germany, where it is the sixth most frequent type of cancer. The development and availability of therapies for liver cancer are critical in the prevention and treatment of this disease. In Germany, several medicines are utilised to treat liver cancer. Sorafenib (Nexavar), an oral medicine that inhibits the growth of cancer cells and has been demonstrated to enhance survival in people with advanced liver cancer, is one of the most regularly utilised therapies. In Germany, other targeted treatments, such as Lenvatinib (Lenvima) and Regorafenib (Stivarga), are used to treat liver cancer. Germany's government spends 12.8 % of its GDP on healthcare.

Germany Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Several advancements in liver cancer therapies have occurred in Germany in recent years. The advent of targeted medicines such as sorafenib and lenvatinib, which have been found to be effective in treating advanced HCC, has been one of the important growth reasons. Furthermore, progress has been made in the development of immunotherapies for liver cancer, with medications like nivolumab and pembrolizumab showing promise in clinical trials. Germany has a low structural unemployment rate and an extensive apprenticeship programme. These aspects could boost the German Liver Cancer Therapeutics market.

Market Restraints

In comparison to other countries of the world, Germany has a low incidence of liver cancer. As a result, clinical trial patient populations may be constrained, slowing the development and approval of new medicines. Despite immigration, the labour force is predicted to shrink beginning in 2020. These factors may deter new entrants into the German Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

  • Bayer AG - Bayer AG is a German multinational pharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as sorafenib (Nexavar) and regorafenib (Stivarga)
  • Merck KGaA - Merck KGaA is a German multinational pharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as pembrolizumab (Keytruda)
  • Affimed GmbH - Affimed GmbH is a German biopharmaceutical company that develops immuno-oncology therapies for the treatment of a range of cancers, including liver cancer. The company's lead drug candidate, AFM13, is currently in clinical trials for the treatment of liver cancer
  • SIRION Biotech GmbH - SIRION Biotech GmbH is a German biotechnology company that develops viral vector technologies for the delivery of gene therapies for the treatment of a range of diseases, including liver cancer
  • apceth Biopharma GmbH

Healthcare Policies and Reimbursement Scenarios

In Germany, the regulation of liver cancer therapeutics is overseen by the Federal Institute for Drugs and Medical Devices (BfArM). Regarding reimbursement, Germany has a comprehensive public healthcare system that provides coverage for its citizens and residents. The healthcare system is managed by the statutory health insurance (SHI) system and is based on the principle of mandatory health insurance.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company Overview Product Applications and Services Recent Developments Partnerships Ecosystem Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Other Types

By Treatment (Revenue, USD Billion):

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Ablation Therapy
  • Embolization Therapy

By Equipment (Revenue, USD Billion):

  • Computed Radiography
  • MRI
  • Sonography
  • Others

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Intravenous

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.


Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:



Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.



Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

In Germany, the regulation of liver cancer therapeutics is overseen by the Federal Institute for Drugs and Medical Devices (BfArM).

The healthcare system is managed by the statutory health insurance (SHI) system and is based on the principle of mandatory health insurance in Germany.

The Liver Cancer Therapeutics in Germany is dominated by a few domestic pharmaceutical companies such as Bayer AG, Merck KGaA and Affimed.

This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 08 December 2023
Updated by: Riya Doshi

Related reports (by category)

Related reports (by geography)

subscribe to our newsletter